
|Articles|April 22, 2022
Spending on US Medicines Rose 12% in 2021 Due to COVID-19 Vaccines and Therapies, Says IQVIA Institute for Human Data Science
Advertisement
Spending on medicines in the United States, at estimated net manufacturer prices, reached $407 billion in 2021, up 12% over 2020, as COVID-19 vaccines and therapeutics became widely available and added $29 billion in related spending. That’s according to a new U.S. Medicines Trends 2022 Report, released today by the IQVIA Institute for Human Data Science. In the same year, the non-COVID medicines market grew more slowly, at 5%, from the growing impact of biosimilars, which increased significantly, offsetting increased use of branded medicines.
Read more about the report and its findings
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons
2
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
3
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung
4
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
5




